Murine tumor antigens: Is it worth the search?

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 622-627

  Jaffee, Elizabeth M ^a   Pardoll, Drew M ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN DETECTION; CYTOTOXIC T LYMPHOCYTE; ENVELOPE GENE; MOUSE; NONHUMAN; POINT MUTATION; SHORT SURVEY; T LYMPHOCYTE; TUMOR; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 0030271710     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80077-X     Document Type: Article

References (47)

1. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:1943;326-333.
2. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13:1953;835-837.
3. Baldwin RW. Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors. Br J Cancer. 9:1955;652-665.
4. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 18:1957;769-778.
5. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20:1960;1561-1572.
6. Old LJ, Boyse EA, Clark DA, Carswell EA. Antigenic properties of chemically-induced tumors. Ann NY Acad Sci. 101:1962;80-106.
7. Globerson A, Feldman M. Antigenic specificity of benzo(a) pyrene-induced sarcomas. J Natl Cancer Inst. 32:1964;1229-1243.
8. Srivastava PK, Old L. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today. 9:1988;78-83.
9. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst. 53:1974;1333-1336.
10. Vasage J. Nonvirus-associated antigens in virus-induced mouse mammary tumors. Cancer Res. 28:1968;2477-2483.
11. Morton DL, Miller GF, Wood DA. Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas. J Natl Cancer Inst. 42:1969;289-301.
12. Carswell EA, Wanebo HJ, Old LJ, Boyse EA. Immunogenic properties of reticulum cell sarcomas of SJL/J mice. J Natl Cancer Inst. 44:1970;1281-1288.
13. Koch S, Zaleberg JR, McKenzie IFC. Description of a murine B lymphoma tumor-specific antigen. J Immunol. 133:1984;1070-1077.
14. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora J-P, Wolfel T, Sibille C, Chomez P, Boon T. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci USA. 85:1988;2274-2278.
15. d by cytolytic T cells. Cell. 58:1989;293-303.
16. Rotzschke O, Falk K, Walllny H-J, Faath S, Rammensee H-G. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-y. Nature. 348:1990;283-287.
17. Van Bleek G, Nathanson S. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature. 348:1990;213-216.
18. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 264:1994;716-719.
19. Mandelbolm O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature. 369:1994;67-71.
20. Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen E, Maryanski JL, De Bergeyck V, Boon T. Structure of the gene of tum-transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med. 172:1990;35-45.
21. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene syngeneic DBA/2 mice. J Exp Med. 173:1991;1373-1384.
22. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, et al. The immunodominant MHC class 1-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product of outstanding interest. Proc Natl Acad Sci USA. 1996; An identified immunodominant tumor antigen expressed by a carcinogen-induced murine colorectal tumor was demonstrated to be the gene product of an activated endogenous retrovirus env gene not expressed in normal tissues. This antigen may represent a distinct class of tumor antigens also expressed by some human tumors. In addition, this antigen may be demonstrated to be a shared tumor antigen.
23. Hayashi H, Matsubara H, Yokota T, Kuwabra I, Kanno M, Koseki H, Isono K, Asano T, Taniguchi M. Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection. J Immunol. 149:1992;1223-1229.
24. O'Donnell PV, Stockert E, Obata Y, Old LJ. Leukemogenic properties of AKR dualtropic (MCF) viruses: amplification of murine leukemia virus-related antigens on thymocytes and acceleration of leukemia development in AKR mice. Virology. 112:1981;548-563.
25. Hartley JW, Wolford NK, Old LJ, Rowe WP. A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci USA. 74:1977;789-792.
26. Nowinski RC, Hays EF, Doyle T, Linkhart S, Medeiros E, Pickering R. Oncornaviruses produced by murine leukemia cells in culture. Virology. 81:1977;363-370.
27. Timmons PM, Brickell PM, Latchman DS, Rigby PW. Activation of endogenous retroviral transcription in SV40-transformed mouse cells. Nucleic Acids Res. 19:1991;7215-7218.
28. Bookman MA, Swerdlow R, Matis LA. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol. 139:1987;3166-3170.
29. + cytolytic clones which recognize a tumor-specific cell surface antigen. J Immunol. 135:1985;703-713.
30. Ono M, Kawakami M, Takezawa T. A novel human nonviral retroposon derived from an endogenous retrovirus. Nucleic Acids Res. 15:1987;8725-8737.
31. Ono M. Molecular cloning and long terminal repeat sequences of human endogenous retrovirus genes related to types A and B retrovirus genes. J Virol. 58:1986;937-944.
32. Medstrand P, Blomberg J. Characterization of novel reverse transcriptase encoding human endogenous retroviral sequences similar to Type A and Type B retroviruses: differential transcription in normal human tissues. J Virol. 67:1993;6778-6787.
33. Ono M, Yasunaga T, Miyata T, Ushikubo H. Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome. J Virol. 60:1986;589-598.
34. Sauter M, Schommer S, Kremmer E, Remberger K, Dolken G, Lemm I, Buck M, Best B, Neumann-Haefelin D, Mueller-Lantzsch N. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol. 69:1995;414-421.
35. Wahlstrom T, Suni J, Nieminen P, Narvanen A, Lehtonen T, Vaheri A. Renal cell adenocarcinoma and retrovirus p30-related antigen excreted to urine. Lab Invest. 53:1985;464-469.
36. Moyret CF, Bernard DJ, Maruizis JC, Chollet P, Plagne R. Detection of reverse transcriptase activity in human breast tumors. Anticancer Res. 8:1988;1279-1283.
37. Moshier JA, Luk GD, Huang RC. mRNA from human colon tumor and mucosa related to the POL gene of an endogenous A-type retrovirus. Biochem Biophys Res Commun. 139:1986;1071-1077.
38. Vogetseder W, Dumfahrt A, Mayersbach P, Schonitzer D, Dierich MP. Antibodies in human sera recognizing a recombinant outer membrane protein encoded by the envelope gene of the human endogenous retrovirus K. AIDS Res Hum Retroviruses. 9:1993;687-694.
39. Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E. Identification of a unique antigen peptide pRL1 on BALB/c RL1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med. 180:1994;1599-1607.
40. Belacosa A, Franke TF, Gonzalez-Portal ME, Datta K, Taguchi T, Gardner J, Cheng JQ, Testa JR, Tsichlis PN. Structure, expression, and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogne. 8:1993;745-749.
41. + T-cell-dependent surveillance. Cancer Res. 50:1990;3851-3858.
42. Rosenstein M, Eberlein TJ, Rosenberg SA. Adoptive Immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. J Immunol. 132:1984;2117-2122.
43. Golumbek P, Lezenby A, Levitsky H, Jaffee L, Karasuyama H, Baker M, Pardoll D. Treatment of established renal cancer by tumor cells engineered to secrete IL-4. Science. 254:1991;713-716.
44. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hirofumi H, Pardoll D, Mulligan Rc. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent antitumor immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
45. - lymphocytes. J Exp Med. 154:1981;952-963.
46. - T cells do not necessarily require recruitment of hosts cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 133:1984;1671-1676.
47. + T cell antigen to be directly isolated and identified is demonstrated to be the mutated product of a normal ribosomal protein. This antigen is uniquely expressed by a UV-induced regressor tumor. Unlike most human tumors, this tumor spontaneously regresses in vivo, and therefore raises the following issue: do murine antigens expressed by regressing tumors represent models for studying human tumor antigens?